Response of osteogenic sarcoma to the combination of etoposide and cyclophosphamide as neoadjuvant chemotherapy
Article Abstract:
Osteogenic sarcoma is a bone cancer in which tumor forms bone-like tissue; it is the leading cause of bone cancer in young people. In an attempt to identify new treatment protocols for osteogenic sarcoma, 17 recently diagnosed patients, ranging in age from 4 to 21, were treated with combinations of etoposide and cyclophosphamide. The response to treatment was evaluated by observing symptoms, X-ray examination, and measurement of the enzyme serum alkaline phosphatase (SAP) in the blood. Fifteen patients showed some response, and 14 (82 percent) showed responses, as indicated by X-rays. Of the five patients who had metastatic (spread of cancer to other areas) tumor at the time of diagnosis, three showed complete or partial response to treatment. All patients who maintained clinical and radiologic responses to treatment also maintained normal levels of the enzyme serum alkaline phosphatase. However, one patient experienced a slight fall in SAP levels after treatment, and an increase in SAP concentration was noted when the patient subsequently relapsed. Although some studies have shown that initial SAP level at diagnosis correlates with outcome, this is the first report of using SAP measurement to assess early treatment. The preliminary evidence suggests that etoposide and cyclophosphamide may be valuable for the treatment of osteogenic sarcoma, but long-term follow-up will be necessary to determine the contribution of these drugs to survival. (Consumer Summary produced by Reliance Medical Information, Inc.)
Publication Name: Cancer
Subject: Health
ISSN: 0008-543X
Year: 1990
User Contributions:
Comment about this article or add new information about this topic:
Phase II study of high-dose cisplatin, etoposide, and cyclophosphamide for refractory ovarian cancer
Article Abstract:
The use of high doses of drug treatment for ovarian cancer that has previously not responded to chemotherapy may not improve the cure rate. Researchers prescribed high doses of cyclophosphamide, etoposide, and cisplatin in two cycles to 48 patients with progressive or persistent ovarian cancer. Six patients died in the course of treatment (12.5%). Twenty-eight patients had measurable cancer, and 25% of them responded to treatment. Patients with minimal disease and platinum-sensitive disease experienced longer survival. High dosage drug treatments for cancer need to weigh toxicity against potential benefits.
Publication Name: American Journal of Obstetrics and Gynecology
Subject: Health
ISSN: 0002-9378
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. Effect of postoperative transfusions on survival in osteosarcoma treated by multimodal therapy
- Abstracts: Effective surgical adjuvant therapy for high-risk rectal carcinoma. Fluorouracil plus levamisole as effective adjuvent therapy after resection of stage III colon carcinoma: a final report
- Abstracts: The value of squamous cell carcinoma antigen in patients with locally advanced cervical cancer undergoing neoadjuvant chemotherapy. part 2
- Abstracts: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening
- Abstracts: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer